This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study

Study Primary Completion Date: February 2008

Intervention(s) in this Clinical Trial

• Drug: brimonidine 0.1% (Alphagan® P)
  • Brimonidine 0.1%, 1 drop three-times daily for 4 weeks

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: 1

Primary Measures

• mean IOP for 24-hour period at 4 weeks
  • Time Frame: 1 Month
    Safety Issue?: No

Secondary Measures

• ocular perfusion pressure
  • Time Frame: 1 Month
    Safety Issue?: No

Inclusion Criteria:

• patients with open-angle glaucoma or ocular hypertension

Exclusion Criteria:

• allergy to brimonidine
• inability to complete 24 hour stay for monitoring

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 40 Years

Maximum Age for this Clinical Trial: 80 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Allergan

Overall Clinical Trial Officials and Contacts

Medical Affairs Study Director Allergan  

Overall Contact: Allergan Inc.  clinicaltrials@allergan.com

Information obtained from ClinicalTrials.gov on November 20, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00457795

Study ID Number: MA-080806-2

ClinicalTrials.gov Identifier: NCT00457795

Health Authority: United States: Institutional Review Board